NASDAQ:LMAT LeMaitre Vascular (LMAT) Stock Price, News & Analysis $81.78 +0.09 (+0.11%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$81.82 +0.03 (+0.04%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LeMaitre Vascular Stock (NASDAQ:LMAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LeMaitre Vascular alerts:Sign Up Key Stats Today's Range$81.08▼$82.5350-Day Range$78.70▼$92.6052-Week Range$71.42▼$109.58Volume467,754 shsAverage Volume170,073 shsMarket Capitalization$1.85 billionP/E Ratio41.30Dividend Yield0.98%Price Target$97.83Consensus RatingHold Company OverviewLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Read More… LeMaitre Vascular Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreLMAT MarketRank™: LeMaitre Vascular scored higher than 56% of companies evaluated by MarketBeat, and ranked 429th out of 926 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingLeMaitre Vascular has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageLeMaitre Vascular has received no research coverage in the past 90 days.Read more about LeMaitre Vascular's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.86% Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 11.86% in the coming year, from $1.94 to $2.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 41.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.61.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 41.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.80.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LeMaitre Vascular's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.43% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 0.77%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldLeMaitre Vascular has a dividend yield of 0.98%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 40.40%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 36.87% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.Read more about LeMaitre Vascular's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.43% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in LeMaitre Vascular has recently decreased by 0.77%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment1.27 News SentimentLeMaitre Vascular has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for LeMaitre Vascular this week, compared to 5 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,556,857.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of LeMaitre Vascular is held by insiders.Percentage Held by Institutions84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LeMaitre Vascular's insider trading history. Receive LMAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter. Email Address LMAT Stock News HeadlinesLeMaitre Vascular: Scaling Nicely As Global Demand BuildsJune 17, 2025 | seekingalpha.com1 Small-Cap Stock with Exciting Potential and 2 to Keep Off Your RadarJune 16, 2025 | finance.yahoo.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 22, 2025 | American Alternative (Ad)3 Low-Volatility Stocks in Hot WaterJune 10, 2025 | msn.comLeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Intrinsic Value Is Potentially 17% Below Its Share PriceMay 31, 2025 | finance.yahoo.comLeMaitre Vascular’s SWOT analysis: niche market leader faces valuation hurdlesMay 24, 2025 | uk.investing.comLMAT Q1 Earnings Call: Sales Growth Outpaces Expectations, Margin Pressures AddressedMay 16, 2025 | msn.com1 Cash-Heavy Stock That Stand Out and 2 to QuestionMay 9, 2025 | finance.yahoo.comSee More Headlines LMAT Stock Analysis - Frequently Asked Questions How have LMAT shares performed this year? LeMaitre Vascular's stock was trading at $92.14 at the beginning of 2025. Since then, LMAT stock has decreased by 11.2% and is now trading at $81.78. View the best growth stocks for 2025 here. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings data on Thursday, May, 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by $0.02. The business's revenue was up 12.0% compared to the same quarter last year. Read the conference call transcript. Does LeMaitre Vascular have any subsidiaries? LeMaitre Vascular subsidiaries include these companies: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and others. Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's top institutional shareholders include Conestoga Capital Advisors LLC (7.28%), Vanguard Group Inc. (7.00%), Copeland Capital Management LLC (4.78%) and Geneva Capital Management LLC (3.82%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Lawrence J Jasinski, John A Roush and Bridget A Ross. View institutional ownership trends. How do I buy shares of LeMaitre Vascular? Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Record date for 3/27 Dividend3/13/2025Ex-Dividend for 3/27 Dividend3/13/2025Dividend Payable3/27/2025Last Earnings5/01/2025Record date for 5/29 Dividend5/15/2025Ex-Dividend for 5/29 Dividend5/15/2025Dividend Payable5/29/2025Today6/21/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LMAT CIK1158895 Webwww.lemaitre.com Phone(781) 221-2266Fax781-425-5049Employees490Year Founded1983Price Target and Rating Average Stock Price Target$97.83 High Stock Price Target$110.00 Low Stock Price Target$93.00 Potential Upside/Downside+19.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$1.98 Trailing P/E Ratio41.30 Forward P/E Ratio42.15 P/E Growth2.16Net Income$44.04 million Net Margins19.96% Pretax Margin25.78% Return on Equity13.53% Return on Assets9.78% Debt Debt-to-Equity Ratio0.48 Current Ratio16.49 Quick Ratio13.83 Sales & Book Value Annual Sales$219.86 million Price / Sales8.40 Cash Flow$2.39 per share Price / Cash Flow34.20 Book Value$15.00 per share Price / Book5.45Miscellaneous Outstanding Shares22,590,000Free Float20,448,000Market Cap$1.85 billion OptionableOptionable Beta0.83 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:LMAT) was last updated on 6/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. E...True Market Insiders | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.